Zymeworks Inc.ZYME
ASignal's systematic analysis rates ZYME as Neutral.
Reflects the latest available analysis · analyzed Aug 24, 2026
The case on ZYME
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong technical momentum with RSI above 70 and MACD above signal line
- Price trading above 20-day and 50-day moving averages
- High cash position relative to debt (debt-to-equity of 0.20x)
- Current ratio of 6.32x indicates strong short-term liquidity
- Overbought RSI at 76.69, increasing reversal risk
- Negative operating and gross margins (operating margin: -918.95%, gross margin: -246.66%)
- Severe revenue contraction (YoY growth: -90.60%)
- Negative free cash flow and operating cash flow (-$65.06M and -$119.34M respectively)
- Extremely high valuation metrics (Price/Sales: 53.99x, EV/Revenue: 47.94x)
- Negative ROE (-72.31%) and ROA (-24.15%) indicating poor capital efficiency
See the full verdict on ZYME
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ZYME
Most investors never get a second opinion, let alone several. ASignal runs ZYME past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.